Power up your LNP and AAV sample prep with Unagi
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.
List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.
Researchers say a newly developed lab technique could spark a “paradigm shift” in biopharmaceuticals testing, promising to speed up drug discovery and development of protein-based drugs.
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
A geometric deep-learning model is faster and more accurate than state-of-the-art computational models, reducing the chances and costs of drug trial failures.
Using an AI algorithm that models drug and target protein interactions, researchers achieved up to 97 percent accuracy in identifying promising drug candidates.
Discover how picodroplet microfluidic technologies can identify and isolate 'hit' cells, quantify varying concentrations of antigen-specific antibodies and much more.
Ensuring that drug candidates can reach the clinic is no easy task, so having models that can closely represent human pathology is crucial. Here, Dr Beth Hoffman, CEO of Origami Therapeutics, describes the successes and challenges of using human disease cell models in drug discovery.
In the search for a rapid, easy way to identify drugs to fight SARS-CoV-2, researchers from across the US came together to develop and apply a high-throughput ADP-ribosylhydrolase assay, ADPr-Glo. Here, Dr Veronica Busa and Dr Anthony Leung from Johns Hopkins University describe the ADPr-Glo assay and how it can be…
Researchers have used a high-throughput assay to screen for potential small molecule SARS-CoV-2 replication inhibitors.
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.
Researchers screened biologically active small molecules, finding several compounds with the ability to induce training effects on macrophages.
A report has found that rapidly evolving R&D infrastructure will help to drive the high-content screening market forwards.
Included in this ebook are pieces on how an assay for the detection of sepsis was developed and a new high-throughput assay that could reveal new drugs to fight COVID-19.